Ionis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.03 Insider Own0.30% Shs Outstand141.60M Perf Week-4.71%
Market Cap5.20B Forward P/E- EPS next Y-2.80 Insider Trans-1.78% Shs Float140.69M Perf Month-4.85%
Income-3.90M PEG- EPS next Q-0.61 Inst Own89.60% Short Float5.07% Perf Quarter12.73%
Sales840.80M P/S6.18 EPS this Y93.60% Inst Trans1.62% Short Ratio6.56 Perf Half Y29.54%
Book/sh5.01 P/B7.51 EPS next Y-13.20% ROA-0.20% Target Price47.28 Perf Year1.02%
Cash/sh14.86 P/C2.53 EPS next 5Y- ROE-0.60% 52W Range25.04 - 44.42 Perf YTD23.66%
Dividend- P/FCF127.07 EPS past 5Y16.50% ROI-1.90% 52W High-15.29% Beta0.76
Dividend %- Quick Ratio9.80 Sales past 5Y16.80% Gross Margin98.50% 52W Low50.28% ATR1.88
Employees660 Current Ratio9.90 Sales Q/Q27.20% Oper. Margin-0.50% RSI (14)50.03 Volatility4.32% 5.21%
OptionableYes Debt/Eq1.76 EPS Q/Q27.90% Profit Margin-0.50% Rel Volume1.49 Prev Close36.65
ShortableYes LT Debt/Eq1.76 EarningsMay 04 BMO Payout- Avg Volume1.09M Price37.63
Recom2.70 SMA201.69% SMA50-1.09% SMA2009.58% Volume1,617,231 Change2.67%
Mar-31-22Resumed Piper Sandler Overweight $54
Mar-01-22Initiated Guggenheim Buy $64
Mar-01-22Initiated Citigroup Sell $26
Feb-01-22Downgrade BofA Securities Buy → Underperform $40 → $30
Dec-14-21Upgrade William Blair Mkt Perform → Outperform
May-07-21Upgrade UBS Sell → Neutral $33 → $37.50
Mar-01-21Upgrade Barclays Underweight → Equal Weight $50 → $52
Dec-16-20Initiated UBS Sell $34
Dec-15-20Upgrade Cowen Market Perform → Outperform
Sep-14-20Resumed JP Morgan Neutral $63
Sep-02-20Initiated The Benchmark Company Hold
Jun-01-20Resumed Oppenheimer Outperform
May-13-20Initiated RBC Capital Mkts Outperform $71
Mar-05-20Initiated Citigroup Buy $73
Dec-13-19Initiated Oppenheimer Outperform
Nov-13-19Initiated BofA/Merrill Buy $70
Nov-07-19Downgrade Morgan Stanley Equal-Weight → Underweight $63 → $48
Sep-10-19Upgrade Bernstein Mkt Perform → Outperform
Aug-08-18Reiterated Stifel Hold $48 → $47
Aug-07-18Reiterated Stifel Hold $55 → $48
May-12-22 07:05AM  
May-06-22 07:23AM  
May-05-22 11:45AM  
May-04-22 08:15AM  
May-02-22 07:05AM  
Apr-27-22 03:03PM  
Apr-20-22 07:05AM  
Apr-04-22 12:15AM  
Mar-29-22 01:03PM  
Mar-28-22 07:30AM  
Mar-21-22 07:05AM  
Mar-16-22 07:16PM  
Mar-07-22 07:05AM  
Mar-01-22 07:05AM  
Feb-25-22 10:58AM  
Feb-24-22 08:15AM  
Feb-17-22 03:02PM  
Feb-10-22 07:05AM  
Feb-08-22 09:38AM  
Feb-07-22 07:30AM  
Feb-01-22 11:43AM  
Jan-31-22 04:17PM  
Jan-25-22 12:33PM  
Jan-24-22 01:38PM  
Jan-19-22 01:38PM  
Jan-18-22 09:07AM  
Jan-06-22 05:36AM  
Jan-05-22 11:20AM  
Jan-04-22 07:34AM  
Dec-30-21 10:07AM  
Dec-29-21 02:00AM  
Dec-14-21 11:38PM  
Dec-11-21 01:05PM  
Dec-09-21 02:37PM  
Dec-08-21 05:37AM  
Dec-07-21 02:33PM  
Dec-03-21 11:32AM  
Dec-02-21 03:03PM  
Nov-24-21 06:30AM  
Nov-18-21 01:30PM  
Nov-12-21 07:05AM  
Nov-09-21 07:05AM  
Nov-07-21 07:05AM  
Nov-04-21 08:29AM  
Nov-03-21 08:15AM  
Nov-02-21 07:05AM  
Oct-27-21 03:03PM  
Oct-25-21 12:31PM  
Oct-22-21 10:06AM  
Oct-20-21 07:05AM  
Oct-18-21 04:07PM  
Oct-17-21 04:20PM  
Oct-14-21 04:06PM  
Sep-29-21 06:12AM  
Sep-15-21 07:30AM  
Sep-03-21 11:31AM  
Sep-02-21 07:05AM  
Aug-09-21 04:11AM  
Aug-05-21 10:15AM  
Aug-04-21 06:01PM  
Aug-02-21 09:30AM  
Jul-29-21 07:05AM  
Jul-28-21 03:04PM  
Jul-26-21 04:35PM  
Jul-21-21 07:05AM  
Jul-20-21 10:29AM  
Jul-14-21 09:55AM  
Jul-13-21 08:06AM  
Jul-12-21 05:55AM  
Jul-08-21 09:07AM  
Jul-06-21 06:30AM  
Jun-19-21 06:02AM  
Jun-14-21 04:05PM  
Jun-10-21 06:05PM  
Jun-04-21 11:31AM  
Jun-02-21 07:59PM  
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swayze EricEVP ResearchApr 21Sale44.1537816,68920,353Apr 25 08:56 PM
Cadoret-Manier OnaizaEVP, Chf Pdt Str & Oper OfcApr 18Option Exercise0.005,667014,049Apr 19 08:23 PM
O'NEIL PATRICK R.EVP CLO & General CounselApr 12Sale40.066,792272,05734,536Apr 14 06:02 PM
Monia Brett PChief Executive OfficerApr 01Sale37.4935513,30988,662Apr 05 06:27 PM
PARSHALL B LYNNEDirectorJan 18Option Exercise0.005,754079,132Jan 20 08:21 PM
BENNETT C FRANKEVP, Chief Scientific OfficerJan 18Option Exercise0.0018,842061,613Jan 20 08:21 PM
Cadoret-Manier OnaizaEVP, Chf Corp Dev and Cml OffcJan 18Option Exercise0.006,057010,687Jan 20 08:21 PM
HOUGEN ELIZABETH LEVP, Finance & CFOJan 18Option Exercise0.0022,050065,803Jan 20 08:18 PM
O'NEIL PATRICK R.EVP CLO & General CounselJan 18Option Exercise0.0021,086048,094Jan 20 08:18 PM
Monia Brett PChief Executive OfficerJan 18Option Exercise0.0049,475099,944Jan 20 08:17 PM
Swayze EricEVP ResearchJan 18Option Exercise0.0013,809025,104Jan 20 08:16 PM
Schneider EugeneEVP, Chf Clinical Develop OffcJan 18Option Exercise0.0010,400017,575Jan 20 08:16 PM
Geary Richard SEVP, Chief Development OfficerJan 18Option Exercise0.0021,391063,357Jan 20 08:16 PM
Schneider EugeneEVP, Chf Clinical Develop OffcOct 15Option Exercise0.0041707,320Oct 19 06:29 PM
Hayden Michael RDirectorOct 15Option Exercise0.001,777014,222Oct 19 06:29 PM
Reikes Peter NDirectorOct 15Option Exercise0.001,777014,222Oct 19 06:29 PM
KLEIN JOSEPH IIIDirectorJul 15Option Exercise0.008,666022,460Jul 19 08:14 PM
BERTHELSEN SPENCER RDirectorJul 15Option Exercise0.008,6660109,649Jul 19 08:13 PM
Hayden Michael RDirectorJul 15Option Exercise0.007,111012,445Jul 19 08:13 PM
WENDER JOSEPH HDirectorJul 15Option Exercise0.008,666096,971Jul 19 08:17 PM
PARSHALL B LYNNEDirectorJul 15Option Exercise0.008,000073,378Jul 19 08:16 PM
Reikes Peter NDirectorJul 15Option Exercise0.007,111012,445Jul 19 08:16 PM
LOSCALZO JOSEPHChairman of BoardJul 15Option Exercise0.008,666025,974Jul 19 08:14 PM
MUTO FREDERICK TDirectorJul 15Option Exercise0.008,666040,349Jul 19 08:15 PM
HERMAN JOAN EDirectorJul 15Option Exercise0.007,111016,000Jul 19 08:13 PM
KLEIN JOSEPH IIIDirectorJul 15Sale35.304,334152,98918,126Jul 19 08:14 PM
BERTHELSEN SPENCER RDirectorJun 23Option Exercise9.3015,000139,500115,983Jun 25 05:19 PM
BERTHELSEN SPENCER RDirectorJun 23Sale37.7415,000566,100100,983Jun 25 05:19 PM
MUTO FREDERICK TDirectorJun 15Option Exercise9.3015,000139,50036,683Jun 17 05:05 PM
MUTO FREDERICK TDirectorJun 15Sale36.6315,000549,50031,683Jun 17 05:05 PM
HERMAN JOAN EDirectorJun 10Option Exercise0.003,55508,889Jun 14 06:46 PM